>The cfo leaving shouldn't bother you because there weren't any revenues to screw around with.<
DNDN doesn’t have any material revenues either, and yet the announcement of the CFO’s departure there was a harbinger of poor performance for the stock.
As previously noted, among all of the top executives in a biotech company, the CFO has the least to gain and the most to lose by sticking around when there are problems not fully known to investors.
Market Data 
Markets 
AI
